Canyon: The Largest Interventional Trial in Becker Muscular Dystrophy to Date - European Medical Journal

Canyon: The Largest Interventional Trial in Becker Muscular Dystrophy to Date

Neurology
Download PDF

The publication of this Infographic was funded by Edgewise Therapeutics.

Sevasemten is an investigational agent that is currently not approved for use by any regulatory authority in any territory.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.